**Shinobi Therapeutics Bolsters Leadership with Dr. Laurent Fischer as New Board Chair**

Cambridge, MA – Shinobi Therapeutics, a pioneering company focused on developing immune-evasive induced pluripotent stem cell (iPSC) therapies, has announced the appointment of Dr. Laurent Fischer as the new Chair of its Board of Directors. This strategic move signals Shinobi's readiness to accelerate the development and commercialization of its innovative therapeutic pipeline.

Dr. Fischer brings to Shinobi Therapeutics an impressive track record spanning more than three decades in the biotechnology industry. His expertise lies in leading and successfully exiting groundbreaking biotech companies dedicated to creating and delivering transformative therapies. Notably, Dr. Fischer was instrumental in the growth and success of Adverum Biotechnologies, a gene therapy company recently acquired by Eli Lilly, further solidifying his reputation as a visionary leader in the field.

The appointment of Dr. Fischer comes at a crucial time for Shinobi Therapeutics as the company prepares to advance two of its leading immune-evasive iPSC therapies. These therapies represent a significant advancement in the field of regenerative medicine, offering the potential to overcome the limitations of traditional cell therapies by preventing immune rejection. iPSC-derived therapies hold immense promise for treating a wide range of diseases, including autoimmune disorders, degenerative diseases, and cancer.

"We are thrilled to welcome Dr. Fischer to Shinobi Therapeutics," said [Quote from Shinobi CEO would go here]. "His extensive experience in guiding biotech companies through critical stages of development and commercialization will be invaluable as we advance our iPSC therapies towards clinical trials and ultimately, to patients in need."

Dr. Fischer’s experience extends beyond Adverum Biotechnologies. He has held leadership positions in various other successful biotech ventures, contributing to the development and launch of multiple innovative treatments. His expertise encompasses not only scientific innovation but also strategic planning, financial management, and business development, making him an ideal fit to guide Shinobi Therapeutics through its next phase of growth.

Shinobi Therapeutics is poised to revolutionize cell therapy with its unique approach to creating immune-evasive iPSCs. The addition of Dr. Fischer to the leadership team reinforces the company's commitment to bringing these groundbreaking therapies to market and improving the lives of patients worldwide. The company anticipates significant progress in the coming years as it moves closer to realizing the full potential of its iPSC platform.